According to Agenus 's latest financial reports and stock price the company's current number of shares outstanding is 317,109,000. At the end of 2023 the company had 317,109,000 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Year | Shares Outstanding | Change |
---|---|---|
2023 | 0.31 B | 12.65% |
2022 | 0.28 B | 21.85% |
2021 | 0.23 B | 28.87% |
2020 | 0.17 B | 32.73% |
2019 | 0.13 B | 19.69% |
2018 | 0.11 B | 13.88% |
2017 | 99.07 M | 15.49% |
2016 | 85.78 M | 2.88% |
2015 | 83.38 M | 35.19% |
2014 | 61.67 M | 76.17% |
2013 | 35.01 M | 44.54% |
2012 | 24.22 M | 22.04% |
2011 | 19.84 M | -79.59% |
2010 | 97.22 M | 15.47% |
2009 | 84.2 M | 29.59% |
2008 | 64.97 M | 42.6% |
2007 | 45.56 M | 1.27% |
2006 | 44.99 M | 0.56% |
2005 | 44.74 M | 0.51% |
2004 | 44.51 M | 14.91% |
2003 | 38.73 M | 19.34% |
2002 | 32.46 M | 14.91% |
2001 | 28.24 M |
Company | Shares Outstanding | differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 2,598,734,075 | 719.51% | ๐บ๐ธ USA |
![]() Merck MRK | 2,538,000,000 | 700.36% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 2,099,000,000 | 561.92% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 2,022,000,000 | 537.64% | ๐ฌ๐ง UK |
![]() Celldex Therapeutics CLDX | 47,214,000 | -85.11% | ๐บ๐ธ USA |